Simplify Your Diabetes Management with Omnipod Discover™

Your diabetes data, simplified

With Omnipod Discover™ you can:
 

  • Access your data anytime
  • Review glucose and insulin delivery trends
  • View weekly insights at a glance
  • Explore historical reports
  • Support conversations with your healthcare team
 
Omnipod 5 with no adhesive and device Omnipod 5 with no adhesive and device
Pod shown without the necessary adhesive. Screen shown for illustrative purposes only.

Built to work with Omnipod® 5

Omnipod® 5 is an automated insulin delivery system (AID) designed to help simplify diabetes management.

  • Proactively helps to correct highs and protect from lows1-2 
  • No multiple daily injections or tangled tubes 
  • Shown to lower A1C1-2-3 
  • Delivered more than 80% time in range with optimised settings4
Learn more about Omnipod 5

4. Sawyer A, et al. Diabetes Technol Ther. 2026. Retrospective RWE of T1D users utilizing optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥5 bolus/day. Optimized settings: CF x TDI ≤1500 (83 mmol/L), I:C Ratio x TDI ≤350, Average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). 
 

Why people choose Omnipod® 5?

Tubeless

No tubes, no tangles.

Podder, Dan, in the park getting ready for a run Podder, Dan, in the park getting ready for a run

Wearable

Place the Pod almost anywhere you’d normally inject insulin.

woman sitting in bed drinking a coffee woman sitting in bed drinking a coffee

Waterproof‡

Shower, swim, or exercise without removing it.

young girl jumping out of the water in a swimming pool young girl jumping out of the water in a swimming pool

Ready to experience more than Automated Insulin Delivery?

Discover how Omnipod® 5 combines tubeless automated insulin delivery with valuable data insights through Omnipod Discover™.

Explore Omnipod® 5

‡ The Pod has a waterproof IP28 rating for up to 7.6 metres for 60 minutes. The PDM/Controller is not waterproof.

1. Brown S. et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Average time with low blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 2.9% vs. 1.3%; 2.2% vs. 1.8%. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents and children = 64.7% vs. 73.9%; 52.5% vs. 68.0%.

2. Sherr JL, et al. Diabetes Care (2022). Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 39.4% vs. 29.5%. Average time with low blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 3.43% vs. 2.46%. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%.

3. Renard E et al. Diabetes Care. 2024. doi:10.2337/dc24-1550. A 13-week randomised control trial conducted among 194 adults (age 18-70 years) with type 1 diabetes in France and the U.S., comparing the safety and effectiveness of the Omnipod 5 Automated Insulin Delivery (AID) System versus conventional non-AID pump therapy and CGM (control). Mean change in HbA1c at 13-weeks: Control = -0.68% or -7.4 mmol/mol, Omnipod 5 = -1.24% or -13.6 mmol/mol. Mean adjusted difference Omnipod 5—control = -0.58% or -6.3 mmol/mol, P<0.0001.Study funded by Insulet

4. Sawyer A, et al. Diabetes Technol Ther. 2026. Retrospective RWE of T1D users utilizing optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, and ≥5 bolus/day. Optimized settings: CF x TDI ≤1500 (83 mmol/L), I:C Ratio x TDI ≤350, Average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L).